Published on FierceBiotech (http://www.fiercebiotech.com)

14. Abbott - Top 15 R&D Budgets

By maureen
Created Nov 15 2007 - 2:28pm

Who: Abbott

Based: United States

2006 Pipeline Budget: $2.5 billion (€1.71 billion)

2007 Pipeline News: Abbott doesn't post its pipeline, but according to information on clinicaltrials.gov, the company is currently running Phase III trials for additional indications for its blockbuster anti-TNF drug Humira. The company has four other compounds in Phase III and no drug pending FDA approval.

Phase III Pipeline:

> Adalimumab (Humira) - Rheumatoid Arthritis, Crohn's Disease, Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis, Juvenile RA, Ulcerative Colitis, Uveitis, Giant Cell Arteritis
> Levosimendan - Congestive heart failure, Acute Heart Failure, Cardiogenic Shock, Septic Shock
> ABT-335 androsuvastatin calcium - Hypercholesterolemia, Dyslipidemia
> Atrasentan - Cancer, Prostatic Neoplasms
> Pricalcitol - Chronic Renal Insufficiency

Full Pipeline Site: See clinicaltrials.gov [1]

Previous: 13. Bristol-Myers Squibb [2]Index [3]Next: 15. Schering-Plough [4]
Source URL: http://www.fiercebiotech.com/special-reports/14-abbott-top-15-r-d-budgets

Links:
[1] http://www.clinicaltrials.gov/
[2] http://www.fiercebiotech.com/special-reports/13-bristol-myers-squibb-top-15-r-d-budgets
[3] http://www.fiercebiotech.com/special-reports/top-15-r-d-budgets
[4] http://www.fiercebiotech.com/special-reports/15-schering-plough-top-15-r-d-budgets